BRAIN Biotech AG has appointed Johan Jansen-Storbacka as Executive Vice President of the BRAINBiocatalysts' enzyme products business, effective September 1, 2025. This leadership change signals the company's strategic focus on strengthening its enzyme and fermentation operations while integrating research and production activities more closely across the organization.
Jansen-Storbacka brings more than 20 years of experience in biotechnology with extensive expertise in enzyme applications spanning industrial processes, animal nutrition, and home care. He holds an M.Sc. in Engineering and Management as well as an MBA, making him well-suited to lead the company's enzyme products division. He succeeds Rod Sears-Black, who retired on January 1, 2025, with BRAIN Biotech CEO Adriaan Moelker temporarily holding the role during the interim period.
In his new position, Jansen-Storbacka will oversee approximately 140 employees and manage fermentation facilities in the UK along with production sites in continental Europe and the United States. His appointment is strategically important as BRAIN Biotech seeks to enhance its position in the growing market for biological solutions that enable more sustainable products and efficient industrial processes. The company's focus on specialty enzymes serves multiple industries including food, life sciences, and industrial applications.
Adriaan Moelker, CEO of BRAIN Biotech, emphasized the significance of this appointment, stating that Jansen-Storbacka's broad industry background will be valuable in serving diverse end markets. His international experience and leadership skills align with the company's global operations and expansion plans. BRAIN Biotech generated revenue of €54.6 million in the 2023/24 fiscal year with approximately 300 employees, demonstrating the substantial scale of the operations Jansen-Storbacka will now lead.
The appointment reflects the increasing importance of biotechnology in driving sustainable industrial transformation. As industries seek biological alternatives to traditional chemical processes, companies like BRAIN Biotech play a crucial role in developing enzyme-based solutions that reduce environmental impact while maintaining economic viability. More information about the company's operations and technologies can be found at https://www.brain-biotech-group.com.
